Lymphokine-activated killer (LAK) cells: I Interferon-γ synergizes with interleukin-2 to induce LAK cytotoxicity in homogeneous leukemic preparations
- 28 February 1991
- journal article
- Published by Elsevier in Clinical Immunology and Immunopathology
- Vol. 58 (2) , 278-288
- https://doi.org/10.1016/0090-1229(91)90142-w
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Immunotherapy of cancer using interleukin 2: current status and future prospectsImmunology Today, 1988
- The international standard for human interleukin-2Journal of Immunological Methods, 1988
- The IL-2 Receptor β Chain (p70): Role in Mediating Signals for LAK, NK, and Proliferative ActivitiesScience, 1987
- A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptorsNature, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.The Journal of Experimental Medicine, 1987
- Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.The Journal of Experimental Medicine, 1986
- Type I and Type II Interferon ReceptorsJournal of Interferon Research, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982